FDA Submission of AXINON^® GFR(NMR)

Exclusive license agreement with Oxford University

numares announces FDA 510(k) Submission of AXINON System^®, a NMR platform for metabolomics-based, AI-driven Diagnostics

numares and Bruker Corporation sign agreement to enable advanced metabolomics-based clinical diagnostics

numares announces strategic collaboration with Mayo Clinic Laboratories on the development of new diagnostic tests

numares completes another financing round

Start of pan-European multicenter study PARASOL to evaluate metabolite constellations to detect kidney allograft rejection

Launch of AXINON^® renalTX-SCORE^®-U100: first metabolomics-based IVD test for allograft rejection diagnosis after kidney transplantation

Collaboration with Oxford University on the development of Multiple Sclerosis diagnostic test

1,000,000 performed analyses on numares' technology platform

numares completes another financing round

Launch of CE-marked IVD test AXINON^® lipoFIT^®-S100 for comprehensive NMR-based lipoprotein profiling

600,000 performed analyses

Successful completion of studies on kidney transplantation

Cooperation with a German laboratory network: commissioning of a test system for lipoprotein profiling

200,000 performed analyses

Bulk order from a U.S. laboratory chain: installation of multiple test systems for lipoprotein profiling

Successful certification of numares according to EN ISO 13485: 2012 as a manufacturer of in-vitro diagnostics (IVD)

100,000 performed analyses

Certification as per EN ISO 13485:2003

First patent for the determination of lipoproteins in body fluids (lipoprotein profiling)